CA2264819C
(en)
*
|
1996-09-04 |
2010-03-23 |
Intertrust Technologies Corp. |
Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management
|
GB0423653D0
(en)
*
|
2004-10-25 |
2004-11-24 |
Piramed Ltd |
Pharmaceutical compounds
|
CL2007001167A1
(es)
*
|
2006-04-26 |
2008-01-25 |
Genentech Inc |
Compuestos derivados de pirimidina condensada, inhibidores de p13-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicionfarmaceutica.
|
DE602007007323D1
(de)
|
2006-04-26 |
2010-08-05 |
Hoffmann La Roche |
Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor
|
ES2571028T3
(es)
*
|
2006-12-07 |
2016-05-23 |
Genentech Inc |
Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
|
EP2518074B1
(en)
|
2006-12-07 |
2015-07-22 |
F.Hoffmann-La Roche Ag |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
WO2008152390A1
(en)
*
|
2007-06-12 |
2008-12-18 |
F.Hoffmann-La Roche Ag |
Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
|
MX338504B
(es)
*
|
2007-09-12 |
2016-04-20 |
Genentech Inc |
Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
|
CN101932587A
(zh)
*
|
2007-09-24 |
2010-12-29 |
吉宁特有限公司 |
噻唑并嘧啶pi3k抑制剂化合物及使用方法
|
JP5348725B2
(ja)
*
|
2007-10-25 |
2013-11-20 |
ジェネンテック, インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
GB0721095D0
(en)
*
|
2007-10-26 |
2007-12-05 |
Piramed Ltd |
Pharmaceutical compounds
|
US9029411B2
(en)
|
2008-01-25 |
2015-05-12 |
Millennium Pharmaceuticals, Inc. |
Thiophenes and uses thereof
|
WO2009097446A1
(en)
*
|
2008-01-30 |
2009-08-06 |
Genentech, Inc. |
Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
|
NZ602675A
(en)
|
2008-03-18 |
2014-03-28 |
Genentech Inc |
Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
UA106206C2
(ru)
|
2008-06-19 |
2014-08-11 |
Милленниум Фармасьютикалз, Инк. |
Производные тиофена или тиазола и их применение как ингибиторов pi3k
|
MX2011001196A
(es)
*
|
2008-07-31 |
2011-05-30 |
Genentech Inc |
Compuestos de pirimidina, composiciones y metodos de uso.
|
CA2952692C
(en)
|
2008-09-22 |
2020-04-28 |
Array Biopharma Inc. |
Substituted imidazo[1,2b]pyridazine compounds
|
KR101624000B1
(ko)
|
2008-10-01 |
2016-05-24 |
노파르티스 아게 |
헷지호그 경로-관련 장애의 치료를 위한 스무슨드 길항작용
|
TWI378933B
(en)
|
2008-10-14 |
2012-12-11 |
Daiichi Sankyo Co Ltd |
Morpholinopurine derivatives
|
TWI458729B
(zh)
|
2008-10-22 |
2014-11-01 |
Array Biopharma Inc |
作為TRK激酶抑制劑之經取代吡唑并〔1,5-a〕嘧啶化合物
|
TWI558710B
(zh)
|
2009-01-08 |
2016-11-21 |
古利斯股份有限公司 |
具有鋅連接部位的磷酸肌醇3-激酶抑制劑
|
CN102395585A
(zh)
|
2009-01-30 |
2012-03-28 |
米伦纽姆医药公司 |
杂芳基化合物和其作为pi3k抑制剂的用途
|
US9090601B2
(en)
|
2009-01-30 |
2015-07-28 |
Millennium Pharmaceuticals, Inc. |
Thiazole derivatives
|
US8796314B2
(en)
|
2009-01-30 |
2014-08-05 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
JP5709766B2
(ja)
*
|
2009-03-12 |
2015-04-30 |
ジェネンテック, インコーポレイテッド |
造血器腫瘍の治療のためのホスホイノシチド3キナーゼ阻害剤化合物と化学療法剤の併用
|
EP2411398B1
(en)
|
2009-03-24 |
2014-12-17 |
Sumitomo Chemical Company, Limited |
Method for manufacturing a boronic acid ester compound
|
MX2011010105A
(es)
*
|
2009-03-27 |
2012-01-12 |
Pathway Therapeutics Inc |
Sulfonamidas de pirimidinilo y 1,3,5-triazinilo benzimidazol y su uso en terapia de cancer.
|
EP2451811A1
(en)
|
2009-05-27 |
2012-05-16 |
F. Hoffmann-La Roche AG |
Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
|
EP2435438A1
(en)
|
2009-05-27 |
2012-04-04 |
Genentech, Inc. |
Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
|
EP2445346A4
(en)
*
|
2009-06-24 |
2012-12-05 |
Genentech Inc |
OXOHETEROCYCLIC FUSIONED PYRIMIDINE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
MX2012000817A
(es)
|
2009-07-21 |
2012-05-08 |
Gilead Calistoga Llc |
Tratamiento para desordenes del higado con inhibidores pi3k.
|
US8435976B2
(en)
*
|
2009-09-08 |
2013-05-07 |
F. Hoffmann-La Roche |
4-substituted pyridin-3-yl-carboxamide compounds and methods of use
|
ES2557316T3
(es)
|
2009-09-08 |
2016-01-25 |
F. Hoffmann-La Roche Ag |
Compuestos de piridín-3-il-carboxamida 4-sustituidos y métodos de utilización
|
CN102030770B
(zh)
*
|
2009-09-25 |
2012-10-31 |
北京大学 |
一种芳香硼酸酯化合物的制备方法
|
UA108863C2
(ru)
|
2009-09-28 |
2015-06-25 |
Ф. Хоффманн-Ля Рош Аг |
Бензоксепиновые ингибиторы pi3 и их применение
|
NZ599939A
(en)
*
|
2009-10-12 |
2014-02-28 |
Hoffmann La Roche |
Combinations of a pi3k inhibitor and a mek inhibitor
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
MX352661B
(es)
|
2009-11-05 |
2017-12-04 |
Rhizen Pharmaceuticals S A Star |
Moduladores novedosos de benzopiran cinasa.
|
WO2011058025A1
(en)
*
|
2009-11-12 |
2011-05-19 |
F. Hoffmann-La Roche Ag |
N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
|
RU2607635C2
(ru)
*
|
2009-11-12 |
2017-01-10 |
Ф.Хоффманн-Ля Рош Аг |
N-9-замещенные пуриновые соединения, композиции и способы применения
|
CN102791715B
(zh)
|
2009-12-31 |
2016-04-27 |
卡洛斯三世国家癌症研究中心基金会 |
用作激酶抑制剂的三环化合物
|
US9555033B2
(en)
|
2010-02-03 |
2017-01-31 |
Signal Pharmaceuticals, Llc |
Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors
|
US8440651B2
(en)
|
2010-02-22 |
2013-05-14 |
F. Hoffmann-La Roche Ag |
Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use
|
CR20170098A
(es)
|
2010-05-20 |
2017-07-17 |
Array Biopharma Inc |
Compuestos macrociclicos como inhibidores de quinasa trk
|
ES2536780T3
(es)
*
|
2010-07-14 |
2015-05-28 |
F. Hoffmann-La Roche Ag |
Compuestos de purina selectivos para I3 p110 delta, y métodos de uso
|
MX2013001660A
(es)
|
2010-08-11 |
2013-06-03 |
Millenium Pharmaceuticals Inc |
Heteroarilos y usos de los mismos.
|
WO2012021611A1
(en)
|
2010-08-11 |
2012-02-16 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
WO2012021615A1
(en)
|
2010-08-11 |
2012-02-16 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
AU2011316016A1
(en)
|
2010-10-13 |
2013-05-30 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
UA109688C2
(xx)
|
2010-12-16 |
2015-09-25 |
|
Трициклічні інгібітори pі3k та їх застосування
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
EP2667874A4
(en)
*
|
2011-01-27 |
2014-07-30 |
Univ Princeton |
MTOR KINASE INHIBITORS AS ANTIVIRAL AGENTS
|
CN103476767B
(zh)
|
2011-02-09 |
2015-06-10 |
弗·哈夫曼-拉罗切有限公司 |
作为pi3激酶抑制剂的杂环化合物
|
RU2013143747A
(ru)
|
2011-03-21 |
2015-04-27 |
Ф. Хоффманн-Ля Рош Аг |
Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения
|
DK2694075T3
(en)
|
2011-04-01 |
2016-08-01 |
Curis Inc |
Phosphoinositide 3-kinase inhibitor with zinc-binding moiety
|
PL2705029T4
(pl)
|
2011-05-04 |
2019-04-30 |
Rhizen Pharmaceuticals S.A. |
Nowe związki jako modulatory kinaz białkowych
|
CN103857804A
(zh)
|
2011-08-03 |
2014-06-11 |
西格诺药品有限公司 |
作为lkb1状态的预测性生物标志物的基因表达谱的鉴定
|
JP6062442B2
(ja)
*
|
2011-10-13 |
2017-01-18 |
ジェネンテック, インコーポレイテッド |
薬剤誘発性低酸症の治療
|
CN103467482B
(zh)
|
2012-04-10 |
2017-05-10 |
上海璎黎药业有限公司 |
稠合嘧啶类化合物,其制备方法,中间体,组合物和应用
|
EP2852661A1
(en)
|
2012-05-23 |
2015-04-01 |
F. Hoffmann-La Roche AG |
Compositions and methods of obtaining and using endoderm and hepatocyte cells
|
WO2013182668A1
(en)
|
2012-06-08 |
2013-12-12 |
F. Hoffmann-La Roche Ag |
Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
|
PL2870157T3
(pl)
|
2012-07-04 |
2018-01-31 |
Rhizen Pharmaceuticals S A |
Selektywne inhibitory pi3k delta
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
CN102924473B
(zh)
*
|
2012-11-05 |
2015-09-02 |
上海毕得医药科技有限公司 |
一种2-氯-7-碘噻吩并[3,2-d]嘧啶的制备方法
|
JP2016502974A
(ja)
|
2012-12-07 |
2016-02-01 |
ザ ジェネラル ホスピタル コーポレイション |
Pi3k/akt阻害剤化合物とher3/egfr阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用
|
US9782427B2
(en)
|
2013-04-17 |
2017-10-10 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
EA029072B1
(ru)
|
2013-04-17 |
2018-02-28 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
|
WO2014172436A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
|
WO2014172423A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
BR112015026238A8
(pt)
|
2013-04-17 |
2019-12-24 |
Signal Pharm Llc |
composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
|
BR112015026292B1
(pt)
|
2013-04-17 |
2022-04-12 |
Signal Pharmaceuticals, Llc |
Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
|
AU2014254057A1
(en)
|
2013-04-17 |
2015-11-05 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
|
US9604939B2
(en)
|
2013-05-29 |
2017-03-28 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
|
CN104513254B
(zh)
|
2013-09-30 |
2019-07-26 |
上海璎黎药业有限公司 |
稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
|
CN106831721B
(zh)
|
2013-10-16 |
2019-10-22 |
上海璎黎药业有限公司 |
稠合杂环化合物、其制备方法、药物组合物和用途
|
EP3082957B1
(en)
*
|
2013-12-20 |
2022-04-06 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors
|
JP6526065B2
(ja)
|
2014-02-28 |
2019-06-05 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
CN106572990A
(zh)
|
2014-03-13 |
2017-04-19 |
豪夫迈·罗氏有限公司 |
含有雌激素受体调节剂的治疗性组合产品
|
AU2015240465B2
(en)
|
2014-04-04 |
2020-02-27 |
Del Mar Pharmaceuticals |
Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
EP3131551A4
(en)
|
2014-04-16 |
2017-09-20 |
Signal Pharmaceuticals, LLC |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
CN106456776A
(zh)
|
2014-05-21 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
用PI3K抑制剂Pictilisib治疗PR阳性腔性A乳腺癌的方法
|
CN106715456B
(zh)
|
2014-08-12 |
2023-08-29 |
莫纳什大学 |
定向淋巴的前药
|
GB201419102D0
(en)
*
|
2014-10-27 |
2014-12-10 |
Imp Innovations Ltd |
Novel compounds
|
PL3699181T3
(pl)
|
2014-11-16 |
2023-05-22 |
Array Biopharma, Inc. |
Postać krystaliczna wodorosiarczanu (s)-n-(5-((r)-2-(2,5-difluorofenylo) - pirolidyn-1-ylo)-pirazolo[1,5-a]pirimidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu
|
EP3262049B1
(en)
|
2015-02-27 |
2022-07-20 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
CN106146352A
(zh)
*
|
2015-04-16 |
2016-11-23 |
上海医药工业研究院 |
Idelalisib中间体及其制备方法
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
US20160375033A1
(en)
|
2015-06-29 |
2016-12-29 |
Genentech, Inc. |
Methods of treatment with taselisib
|
EP3317283B1
(en)
|
2015-07-02 |
2019-04-03 |
H. Hoffnabb-La Roche Ag |
Benzoxazepin oxazolidinone compounds and methods of use
|
RS59740B1
(sr)
|
2015-07-02 |
2020-02-28 |
Hoffmann La Roche |
Benzoksazepin oksazolidinonska jedinjenja i postupci upotrebe
|
CN105147696A
(zh)
*
|
2015-07-08 |
2015-12-16 |
李荣勤 |
联合使用盐酸二甲双胍和gdc0941的抗乳腺癌颗粒剂及制备方法
|
EP3354653B1
(en)
*
|
2015-07-21 |
2019-09-04 |
Guangzhou Maxinovel Pharmaceuticals Co. Ltd. |
Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
JP7118888B2
(ja)
|
2015-09-08 |
2022-08-16 |
モナッシュ ユニバーシティ |
リンパ指向性プロドラッグ
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
SG11201803099SA
(en)
|
2015-10-23 |
2018-05-30 |
Navitor Pharm Inc |
Modulators of sestrin-gator2 interaction and uses thereof
|
SG11201803438XA
(en)
|
2015-10-26 |
2018-05-30 |
Univ Colorado Regents |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
WO2017106352A1
(en)
|
2015-12-14 |
2017-06-22 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of mthfd2 and uses thereof
|
TW201726685A
(zh)
|
2015-12-31 |
2017-08-01 |
韓美藥品股份有限公司 |
噻吩并嘧啶化合物之鹽酸鹽的結晶型
|
SI3426243T1
(sl)
|
2016-03-09 |
2021-11-30 |
Raze Therapeutics, Inc. |
Zaviralci 3-fosfoglicerat dehidrogenaze in uporabe le-teh
|
PL3426244T3
(pl)
|
2016-03-09 |
2023-09-25 |
Raze Therapeutics, Inc. |
Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
SG11201808559PA
(en)
|
2016-04-04 |
2018-10-30 |
Loxo Oncology Inc |
Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
|
US11337969B2
(en)
|
2016-04-08 |
2022-05-24 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
JP7443057B2
(ja)
|
2016-05-18 |
2024-03-05 |
ロクソ オンコロジー, インコーポレイテッド |
(S)-N-(5-((R)-2-(2,5-ジフルオロフェニル)ピロリジン-1-イル)-ピラゾロ[1,5-a]ピリミジン-3-イル)-3-ヒドロキシピロリジン-1-カルボキサミドの調製
|
US11332470B2
(en)
|
2016-06-21 |
2022-05-17 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
US10988465B2
(en)
|
2016-06-21 |
2021-04-27 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
EP3808748A1
(en)
|
2016-06-21 |
2021-04-21 |
X4 Pharmaceuticals, Inc. |
Substituted piperidines as cxcr4-inhibitors
|
ES2930198T3
(es)
|
2016-10-14 |
2022-12-07 |
Nimbus Lakshmi Inc |
Inhibidores de TYK2 y usos de los mismos
|
JP7082120B2
(ja)
|
2016-10-21 |
2022-06-07 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
EP4035659A1
(en)
|
2016-11-29 |
2022-08-03 |
PureTech LYT, Inc. |
Exosomes for delivery of therapeutic agents
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
CN110603261A
(zh)
|
2016-12-23 |
2019-12-20 |
拜斯科阿迪有限公司 |
具有新型键结构的肽衍生物
|
US10624968B2
(en)
|
2017-01-06 |
2020-04-21 |
Bicyclerd Limited |
Compounds for treating cancer
|
EP4338802A2
(en)
|
2017-03-08 |
2024-03-20 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
US11339144B2
(en)
|
2017-04-10 |
2022-05-24 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl Rheb inhibitors and uses thereof
|
CN116370448A
(zh)
|
2017-04-26 |
2023-07-04 |
纳维托制药有限公司 |
Sestrin-gator2相互作用的调节剂及其用途
|
EP3615550A1
(en)
|
2017-04-27 |
2020-03-04 |
BicycleTx Limited |
Bicyclic peptide ligands and uses thereof
|
EA202090103A1
(ru)
|
2017-06-22 |
2020-04-24 |
Селджин Корпорейшн |
Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b
|
JP7301757B2
(ja)
|
2017-06-26 |
2023-07-03 |
バイスクルアールディー・リミテッド |
検出可能部分を持つ二環式ペプチドリガンドおよびその使用
|
CN117946115A
(zh)
|
2017-07-28 |
2024-04-30 |
武田药品工业株式会社 |
Tyk2抑制剂与其用途
|
EP3668887A1
(en)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
US20200283482A1
(en)
|
2017-08-14 |
2020-09-10 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
AU2018324037A1
(en)
|
2017-08-29 |
2020-04-16 |
Monash University |
Lymphatic system-directing lipid prodrugs
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
CA3076613A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
CN109796465B
(zh)
*
|
2017-11-16 |
2020-07-14 |
华中科技大学同济医学院附属协和医院 |
靶向pet显像化合物、包含该化合物的显象剂及其制备方法和用途
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
BR112020012997A2
(pt)
|
2017-12-26 |
2020-12-01 |
Kymera Therapeutics, Inc. |
degradadores de irak e usos dos mesmos
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
BR112020015396A2
(pt)
|
2018-01-29 |
2020-12-08 |
Merck Patent Gmbh |
Inididores de gcn2 e usos dos mesmos
|
AU2019211485A1
(en)
|
2018-01-29 |
2020-08-06 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
CN117304157A
(zh)
|
2018-02-27 |
2023-12-29 |
阿塔克斯生物制药有限公司 |
作为tcr-nck相互作用的抑制剂的色烯衍生物
|
KR20210005151A
(ko)
|
2018-04-24 |
2021-01-13 |
메르크 파텐트 게엠베하 |
항증식 화합물 및 이의 용도
|
WO2019209757A1
(en)
|
2018-04-24 |
2019-10-31 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
CN112423843B
(zh)
|
2018-06-15 |
2023-11-28 |
詹森药业有限公司 |
雷帕霉素类似物和其用途
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
CN108997372B
(zh)
*
|
2018-07-31 |
2020-07-28 |
华中科技大学同济医学院附属协和医院 |
正电子显像用化合物、其中间体、制备方法和显像剂
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
US20220089587A1
(en)
|
2018-09-07 |
2022-03-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
AU2019340376A1
(en)
|
2018-09-11 |
2021-04-08 |
Curis Inc. |
Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
|
WO2020081508A1
(en)
|
2018-10-15 |
2020-04-23 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
US10919937B2
(en)
|
2018-10-23 |
2021-02-16 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
EP3870158A4
(en)
|
2018-10-24 |
2022-08-10 |
Navitor Pharmaceuticals, Inc. |
POLYMORPHIC COMPOUNDS AND USES THEREOF
|
US11053241B2
(en)
|
2018-11-30 |
2021-07-06 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
EP3903828A4
(en)
|
2018-12-21 |
2022-10-05 |
Daiichi Sankyo Company, Limited |
COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
|
US11174264B2
(en)
|
2019-01-23 |
2021-11-16 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
AU2020253990A1
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
BR112021019748A2
(pt)
|
2019-04-05 |
2021-12-07 |
Kymera Therapeutics Inc |
Degradadores de stat e usos dos mesmos
|
MX2021014441A
(es)
|
2019-05-31 |
2022-01-06 |
Ikena Oncology Inc |
Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
|
TW202110485A
(zh)
|
2019-07-30 |
2021-03-16 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
EP4028385A4
(en)
|
2019-09-11 |
2023-11-08 |
Vincere Biosciences, Inc. |
USP30 INHIBITORS AND USES THEREOF
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
WO2021087432A1
(en)
|
2019-11-01 |
2021-05-06 |
Navitor Pharmaceuticals, Inc. |
Methods of treatment using an mtorc1 modulator
|
BR112022010754A2
(pt)
|
2019-12-05 |
2022-08-23 |
Anakuria Therapeutics Inc |
Análogos de rapamicina e usos dos mesmos
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
MX2022007576A
(es)
|
2019-12-17 |
2022-09-23 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
EP4081308A4
(en)
|
2019-12-23 |
2024-01-24 |
Kymera Therapeutics Inc |
SMARCA DEGRADERS AND USES THEREOF
|
CN115348864A
(zh)
|
2020-02-05 |
2022-11-15 |
纯技术Lyt股份有限公司 |
神经甾体的脂质前药
|
KR20220164706A
(ko)
|
2020-03-03 |
2022-12-13 |
피아이씨 테라퓨틱스 인코포레이티드 |
Eif4e 억제제 및 이의 용도
|
TW202200543A
(zh)
|
2020-03-19 |
2022-01-01 |
美商凱麥拉醫療公司 |
Mdm2降解劑及其用途
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
IL300450A
(en)
|
2020-08-17 |
2023-04-01 |
Bicycletx Ltd |
Bicyclic conjugates specific to nectin-4 and uses thereof
|
WO2022120354A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
KR20230152692A
(ko)
|
2021-02-02 |
2023-11-03 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
JP2024505571A
(ja)
|
2021-02-02 |
2024-02-06 |
リミナル・バイオサイエンシーズ・リミテッド |
Gpr84アンタゴニストおよびその使用
|
JP2024506657A
(ja)
|
2021-02-15 |
2024-02-14 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak4分解剤およびその使用
|
EP4301756A1
(en)
|
2021-03-05 |
2024-01-10 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
CA3229560A1
(en)
|
2021-08-25 |
2023-03-02 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
US20230134932A1
(en)
|
2021-08-25 |
2023-05-04 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
TW202404581A
(zh)
|
2022-05-25 |
2024-02-01 |
美商醫肯納腫瘤學公司 |
Mek抑制劑及其用途
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|